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The ideal drug of modern medicine is the one that achieves its therapeutic target with minimaladverse eﬀects. Immune therapy of
Type 1 diabetes (T1D) is no exception, and knowledge of the antigens targeted by pathogenic T cells oﬀers a unique opportunity
t o w a r d st h i sg o a l .D i ﬀerent antigen formulations are being considered, such as proteins or peptides, either in their native form
or modiﬁed ad hoc, DNA plasmids, and cell-based agents. Translation from mouse to human should take into account important
diﬀerences,particularly inthetimescaleofautoimmuneprogression,andintervention.Criticalparameters such asadministration
route, dosing and interval remain largely empirical and need to be further dissected. T1D staging through immune surrogate
markers before and after treatment willbe key in understanding therapeutic actions and to ﬁnallyturn ordinary blanksinto magic
bullets.
1.Introduction
Type 1 diabetes (T1D), one of the most common autoim-
mune diseases, stems from defects in central and peripheral
tolerance that lead to progressive T-cell-mediated destruc-
tion of insulin-producing β cells in pancreatic islets. Clin-
ically, this destruction results in the inability of aﬀected
individuals to produce the insulin required to properly
regulate glucose metabolism, causing substantial morbidity
and mortality. Although metabolic derangements are only
the consequences of the underlying autoimmune pathogen-
esis, they remain the only targets of mainstream insulin
therapy. Immune-targeted interventions which could correct
autoimmune mechanisms are, therefore, intensively sought
as a more rational approach. Preclinical studies largely
take advantage of the nonobese diabetic (NOD) mouse,
which is one rare instance of autoimmune model, where
disease developsspontaneously rather than being inducedby
experimental manipulation.
2.Translatingthe NOD Mouse into Human
There is a long list of immune biologicsthat have spectacular
eﬀects in preventing T1D in the NOD mouse. However, only
a handful of them has shown some eﬀect once translated
into clinical trials. There are a number of reasons explaining
these discrepancies which should be kept in mind. First
is the phylogenetic diﬀerence between the murine and
human immune system, which is not surprising considering
that the two species diverged ∼70 million years ago [1].
Second, although the NOD is a spontaneous model of
T1D which is linked to MHC susceptibility haplotypes and
involves a complex immune interplay like in human, there
are important discrepancies. These include characteristics
of the insulitis inﬁltrate, autoantibody (aAb) speciﬁcities,
and association with otherautoimmunemanifestations (e.g.,
sialitis). Third, the NOD is an inbred strain composed of
genetically identical animals. As such, it can be assimilated
to one single T1D patient, and indeed a very peculiar one.2 Clinical and Developmental Immunology
Further underrepresenting human disease, these mice are
kept under identical environmental conditions, protected
from most infectious threats. Fourth, disease and treatment
kineticsarequitediﬀerent,as NODmicearemost commonly
treated for preventing diabetes at an early stage, before the
appearance of any circulating autoimmune marker such as
anti-insulin aAbs (IAA). This is rarely possible in humans, as
furtherdiscussed.Indeed,whenwelookatimmunetherapies
which work in the NOD mouse once the disease has become
clinically overt, the list of eﬀective treatments falls much
shorter. The challenge thatintervention trials face in humans
is thus a formidable one. For this reason, we will focus our
discussion on antigen- (Ag-)speciﬁc agents that havealready
been tested or are soon to enter clinical trials, reasoning that
our goal is to cure men rather than mice.
3.Immune TherapyforType1 Diabetes:
Whom for?
Studies in the NOD mouse suggest that the great majority
of the β-cell mass (∼75%) has already been destroyed by
the time of diabetes onset [2]. A recent meta-analysis and
mathematical modeling of three landmark histopathological
studies of human T1D pancreata [3–5] suggests that this is
also the case in humans [6]. However, the extent of β-cell
destruction varies with age, ranging from 85% in children
to 40% in adults [6]. This is probably due to a combination
of factors, which include a physiological age-related decline
in β-cell mass, diﬀerences in insulin needs according to
body weight, growth and insulin sensitivity, and the degree
of β-cell autoimmunity, which may be more aggressive in
younger patients. One limitation of most histopathological
studies is that measurement of residual β-cell mass was
based on enumeration of insulin-positive cells within the
islets. It is, thus, possible that viable β cells not producing
insulin because offunctional impairment are missed, leading
to an overestimation. It is also diﬃcult to relate these
histopathologicalestimates ofresidual β-cell mass with those
of residual β-cell function, as determined by stimulated
C-peptide secretion. However, recent studies suggest that
insulinproductionmaybemoresubstantialatdiagnosisthan
had been previously appreciated and that residual insulin
secretion may persist in a subgroup of T1D patients [7].
Further complicating the picture, the question of whether
signiﬁcant β-cell renewal occurs in T1D patients remains
unsettled [8].
Whichevertherealextentofβ-celldestructionatthetime
ofT1Donset,itisclearthatinterventionsaimedatcorrecting
immune mechanisms should be implemented as early as
possible,ideallyatapreclinicalstagein asyethealthysubjects
at risk of developing disease (Figure 1). A related problem is,
therefore,toreliablyidentify thesesubjects.Althoughgenetic
markers (particularly HLA Class II susceptibility alleles) and
serum aAbs against the β-cell Ags insulin, glutamic acid
decarboxylase (GAD), insulinoma-associated protein 2 (IA-
2), and zinc transporter 8 (ZnT8) greatly help to stratify
T1D risk, they fall short in accuracy, as they can predict the
risk but not the time course of disease development (i.e.,
the “if”, but not the “when”), and much less when only one
aAb marker is present. The accuracy of these predictions
needs to be very stringent if used to decide enrollment into
a clinical trial, because the risk-beneﬁt balance is a delicate
one for T1D. We are not facing a rapidly lethal disease but
rather onethat, despite diﬃcultdaily management and long-
term complications, carries a life expectancy which is getting
closer and closer to normal. This benign prognosis needs
to be weighed against the risks of experimental immune
therapeutics, whose long-term adverse events are frequently
unknown. It is, therefore, ethically acceptable to trial only
those subjects in whom T1D will eventually develop. Given
the eﬀorts and diﬃculties needed to recruit an adequate
number of at-risk subjects, T1D prevention studies have
been quite limited and performed mostly in subjects at
very high risk. Trials in newly diagnosed T1D patients are
more common, with the inner constraint that, even if the
autoimmune process is eﬀectively halted, there is limited
clinical beneﬁt to be expected from rescuing the residual β-
cell mass. This is particularly daunting in T1D children, in
whom the remaining β cells are fewer than in adults and
may be as few as 15% [6]. In this respect, combination
of immune biologics with strategies aimed at replacing
or regenerating lost β cells may expand the optimal time
window for intervention.
4.Immune Suppressionversus
ToleranceRestoration
Two broad strategies could theoretically be followed to inter-
vene on β-cell autoimmunity. The ﬁrst one would consist of
correcting the environmental causes triggering autoimmu-
nity. However, this is certainly the most frustrating failure
of half a century of T1D research, which has elucidated
a wealth of immune mechanisms without identifying the
environmental primi moventes. The only emerging exception
may be the role of the gut microbiome, as data obtained
in the NOD mouse suggests that altering composition
of intestinal ﬂora may oﬀer new treatment paths in the
future [9]. Factors responsible for insulin resistance are
also emerging contributors to T1D development, but they
probably play a precipitating rather than causative role.
Nonetheless, insulin resistance has recently been recognized
as a powerful T1D risk factor [10], and clinical trials with
drugs such as metformin acting on metabolic pathways keep
being investigated [11–13].
The second, currently more viable, strategy is to correct
immune mechanisms. In doing this, an important diﬀerence
needs to be made between immune suppression and toler-
ance restoration. With immune suppression, a generalized
status of lessened reactivity is induced so that the body
has decreased responses to Ag challenges of any kind. This
exposes to increased risks of infection and secondary tumor
growth. Moreover, treatment needs to be lifelong, as its
eﬀects are lost after discontinuation. Immune suppression
is typically induced by drugs that act on common signaling
pathways used by key immune cells. Examples of such
drugs used in the past are cyclosporin A [14]a n d ,i nm o r eClinical and Developmental Immunology 3
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Figure 1: Stages of disease progression and intervention in T1D. Progression over time (X-axis) from simple genetic susceptibility to β-cell
autoimmunity and T1D is plotted against residual β-cell mass (Y-axis). The time points at which immune therapies are administered are
shownin red.
recent years, anti-CD25 monoclonal antibodies (mAbs) and
mycofenolate mofetil, used either alone or in combination
[15].
With immune tolerance restoration, the induced eﬀect
is not generalized but limited to speciﬁc types of responses,
ideally only to responses speciﬁc to β-cell Ags. Thus, the
immune system remains capable of responding to infectious
and tumoral threats. Treatment should be limited in time,
while the eﬀects should persist after discontinuation. This
is because an “active” eﬀect is induced by boosting natural
immunetolerancemechanisms. Withthisframe ofreference,
it is evident why immune restoration strategies are prefer-
able. Given their more selective action and limited duration
of treatment, their risk-beneﬁt balance is more attractive,
especially if they have to be applied in prevention trials.
Although several non-Ag-speciﬁc therapeutic mAbs are also
under scrutiny [16], agents that exploit the target β-cell
A g st h e m s e l v e sm a yo ﬀer the best warranties of Ag-speciﬁc
immune tolerance.
5.Which β-Cell Antigens?
The list of β-cell Ags relevant to T1D autoimmunity is quite
long [17], but few of them have resisted the proof of time
and proved to be key targets of aAb and/or T-cell responses.
These Ags are insulin and its precursors proinsulin (PI) and
preproinsulin (PPI), GAD, IA-2, ZnT8, and islet glucose-6-
phosphatase catalytic subunit-related protein (IGRP). The
latter is the only one to be exclusively described as a target
of T cells [18, 19], as aAbs have been sought after but not yet
found.
A popular tenet in autoimmunity is that there could
be one primary self Ag which initiates pathogenesis. Tissue
destruction through targeting of this Ag could further
release other ones, thus amplifying the autoimmune cascade
through a phenomenon known as epitope spreading. In the
NOD mouse, insulin has been identiﬁed as the initiating
β-cell Ag. The importance of insulin is supported by data
on insulin knockout NOD mice. Diﬀerent from humans,
rodents express two isoforms, referred to as insulin 1 and
2. NOD mice defective for the insulin 2 gene, the prevalent
isoform in the thymus, display accelerated T1D [20], likely
related to defective deletion of insulin-reactive T cells [21].
Conversely, NOD mice defective for the insulin 1 gene, one
of thetwoisoforms expressed in theislets, are less susceptible
to T1D [22]. However, insulin 1 knockout islets transplanted
into recently diabetic wild-type NOD mice become inﬁl-
trated and only transiently reverse T1D, suggesting that
insulin is an early but not exclusive target [22]. More recent
evidence from Nakayama et al. further suggests that insulin
may be the initiating β-cell Ag in T1D [23]. These authors
produced NOD mice, where the endogenous insulin 1 and 2
genes have been deleted and replaced by a hormonally active
insulin transgene carrying a single amino acid mutation at
positionB16.These miceare completelyprotected fromT1D
and insulitis [23]. Intriguingly, the introduced substitution
aﬀects insulin recognition by both CD4+ and CD8+ T cells,
as two overlapping immunodominant epitopes have been
described in this region: insulin B9–23 [24]a n di n s u l i nB 15–23
[25], respectively. These data suggest that recognition of
these immunodominant epitopes by CD4+ and/or CD8+ T
cells may be a mandatory early event in T1D pathogenesis.
Studies by Krishnamurthy et al. further corroborated the
hypothesis that insulin is the initiating Ag in the T1D of the
NOD mouse, because mice rendered tolerant to insulin by
transgenic overexpression of insulin 2 in Ag-presenting cells
do not develop the immunodominant IGRP206–214-speciﬁc
responses andareprotectedfrom T1D[26].Conversely,mice
made tolerant to IGRP by the same means are not protected4 Clinical and Developmental Immunology
from T1D [26], suggesting that IGRP-speciﬁc responses
lay downstream of insulin-speciﬁc ones in the pathogenic
cascade. The prerequisite of insulin-speciﬁc responses for
T1D to develop is even found in NOD8.3 mice, which are
transgenic for a T-cell receptor recognizing the IGRP206–214
epitope [27].
Despite strong evidence pointing to insulin’s triggering
role,identifyingandtargetingmoreβ-cellAgsremainahigh-
priority goal. Several considerations justify these eﬀorts.
First, the evidence supporting insulin’s critical role has
been obtained in the NOD model, but similar evidence in
human T1D is conﬁned to the early appearance of IAA.
Second, once autoimmune T-cell (and B-cell) responses to
β cells are initiated, the speciﬁcity of these responses rapidly
enlargestoincludemore Ags(epitopespreading). Asa result,
responses to the presumable triggering Ag can be rapidly
overgrown by secondary responses, as exempliﬁed by IGRP-
speciﬁc CD8+ T cells, which rapidly outnumber insulin-
speciﬁc cells in the NOD model [28]. This consideration
is particularly relevant in human, as even prevention trials
enroll at-risk subjects at a relatively late stage, once the
ﬁrst signs of β-cell autoimmunity (i.e., aAbs) are already
detectable, and Ag targeting has probably already diversiﬁed.
Third, even among inbred NOD mice kept under identical
environmental exposure, variations exist in the speciﬁcity
of CD8+ T-cell responses [29]. Such variations are certainly
more extensive in the outbred human population. Fourth,
drawing a straight correlation between NOD mice and
humans is a gross approximation even in the case of target
Ags. Indeed, data in the NOD mouse suggest that GAD and
IA-2aredispensableAgs[30,31],whiletheyaremajortargets
of aAbs and T-cell responses in humans, and even promising
therapeutics in the case of GAD [32]. Of the β-cell Ags
described, only insulin and GAD have reached the stage of
clinicaltrialsandwill bediscussed, assummarized inTable 1.
Ag-based biologics can be divided into the following
categories (Figure 2):
(i) whole proteins,
(ii) peptides,
(iii) modiﬁed protein and peptide Ags,
(iv) DNA plasmids,
(v) Ag-speciﬁc cell therapies.
6.Whole Proteins
The main advantage of using whole proteins is that they
coverthe completeamino acid sequencepotentially available
for epitope processing and presentation by Ag-presenting
cells. Contrary to peptide epitopes, one single agent can be
used in all patients, independently of their HLA haplotypes.
However, production of the protein in recombinant form
at suﬃcient purity and clinical grade can be challenging,
as these preparations are frequently spiked with small
contaminants carried over from the host bacteria, yeasts, or
baculoviral systems that need to be removed. Only insulin
and GAD have so far been employed as whole protein agents
for T1D.
6.1. Insulin. The rationale of insulin-based T1D clinical
trials is twofold. First, to restore insulin-speciﬁc immune
tolerance. Second, to put the β cell “at rest”, by providing
hormonally active exogenous insulin, thus avoiding to over-
load the endogenous secretory capacity. Indeed, metabolic
stress could not only precipitate β-cell apoptosis [33], but
also make β cells more immunogenic and thus susceptible
to destruction by autoreactive T cells [34].
Despite this appealing rationale and solid (pre)clinical
grounds obtained in the NOD mouse [35–37] and in small-
scale pilot human studies [38–40], a number of insulin-
based trials, both preventative and interventional, have been
disappointingly unsuccessful. Insulin of human origin was
used in all of these studies. In the diabetes prevention
trial-1 (DPT-1) [41], subjects at high risk of developing
T1D were enrolled. These were deﬁned as being positive
for islet cell aAbs and already displaying early alterations
of insulin secretion, documented by loss of the ﬁrst-phase
insulin response. For such subjects, the projected 5-year risk
is >50%. Participants were treated with parenteral insulin—
subcutaneous injections twice daily, plus annual intravenous
infusions—for amedian followupof3.7years. Subcutaneous
ultralente insulin was administered at a dose of 0.125U/kg
twice daily and intravenous regular insulin given every 12
months for 4 days at a basal rate of 0.015U/kg/h, which
was increased for meals. Despite this intensive treatment,
there was no protection on subsequent T1D development.
Similar results were obtained in a smaller European trial
employing subcutaneous insulin [42]. This outcome is not
as surprising when comparing the DPT-1 strategy with its
founding preclinical studies in the NOD mice [35]. Indeed,
NOD mice were treated at doses of 0.5U per animal, that is,
∼25U/kg, a dose which is 200-fold higher of what was used
in the DPT-1. Regimens like those used in mouse studies
would correspond to 1,750U for an average adult human,
which is far above the maximal tolerable dose. Moreover,
in most studies, NOD mice were treated continuously for
up to 6 months. It is, thus, possible that insulin treated
ongoing diabetes rather than preventing incipient disease
in some animals. The risk of hypoglycemia is a major
concern for translation into human, while mice are quite
resistant to insulin-induced hypoglycemia, possibly due to
stronger counter-regulatory hormone responses. Longer-
acting insulins such as glargine are now available which
display a lower risk of hypoglycemia and constant levels
throughout most of the day. This pharmacokinetic proﬁle
could be interesting not only in widening the therapeutic
window of safe dosage, but also by providing low level
Ag persistence without signiﬁcant pulsatility, which may be
more eﬀective for tolerance induction [43]. Surprisingly, a
mutated insulin (B25Asp) devoid of hypoglycemic activity
(duetovery lowbindingaﬃnity fortheinsulin receptor)and
preserving immunogenicity [44] has never been considered
for clinical trials, despite encouraging studies in the NOD
mouse [45]. B25Asp insulin could be administered at much
higher doses,similar tothose usedin mice,while minimizing
the risk of hypoglycemia.
The DPT-1 trial also comprised an oral arm, in which at-
risk subjects were treated by oral insulin (7.5mg/day) for aClinical and Developmental Immunology 5
Table 1: Clinical trials in T1D using antigen-speciﬁc strategies.
Antigen
type Antigen Formulation Route Trial (Phase) Subjects Outcome and/or
immune biomarkers Reference
Protein Insulin Short-acting insulin Intravenous Intravenous insulin
(Phase I)
Recent-onset
T1D
Higher stimulated C
peptide and lower
HbA1c versus s.c. NPH
insulin
[38]
Protein Insulin
(Ultra)lente/regular
insulin
(s.c.)+short-acting
insulin (i.v.)
Subcutaneous
+ Intravenous
JoslinInsulin
Prophylaxis Trial
(Phase I)
At risk Suggestive of eﬃcacy [39]
Protein Insulin
Lente/short-acting
insulin
(s.c.)+short-acting
insulin (i.v.)
Subcutaneous
+ Intravenous
Schwabing Insulin
Prophylaxis Trial
(Phase I)
At risk Suggestive of eﬃcacy [40]
Protein Insulin
Ultralente insulin
(s.c.)+short-acting
insulin (i.v.)
Subcutaneous
+ Intravenous
DPT-1 Parenteral
arm (Phase III) At risk No eﬀect [41]
Protein Insulin Ultralente insulin Subcutaneous EPPSCIT (Phase II) At risk No eﬀect [42]
Protein Insulin Short-acting insulin Oral ORALE (Phase II) Recent-onset
T1D No eﬀect [46]
Protein Insulin Short-acting insulin Oral IMDIAB VII
(Phase II)
Recent-onset
T1D No eﬀect [47]
Protein Insulin Short-acting insulin Oral DPT-1 Oral arm
(PhaseIII) At risk Some eﬃcacy in IAA+
subjects [49]
Protein Insulin Short-acting insulin Oral
Oral insulin
tolerance
(PhaseIII)
Recent-onset
T1D
1mgimproved
C-peptide responses in
older patients;10mg
accelerated C-peptide
decline in younger
patients
[48]
Protein Insulin Short-acting insulin Oral
NIH/ADA/JDRF
oral insulin
(PhaseIII)
At-risk IAA+ Ongoing NCT
00419562
Protein Insulin Short-acting insulin Intranasal INIT-I (Phase I) At-risk IAA+
Increase in aAb and
decrease in T-cell
proliferative responses
to insulin
[50]
Protein Insulin Short-acting insulin Intranasal DIPP (PhaseIII) At risk No eﬀect [51]
Protein Insulin Short-acting insulin Intranasal
Intranasal insulin in
T1D patients
(Phase II)
Recent-onset,
non-insulin-
dependent
T1D
No eﬀect; decrease in
IFN-γ T-cell responses
to PI; decrease in Ab
responses to exogenous
insulin
[52]
Protein Insulin Short-acting insulin Intranasal INIT-II (Phase II)
At risk with
preserved 1st
phase insulin
response
Ongoing NCT
00336674
Protein Insulin Short-acting insulin Oral or
Intranasal Pre-POINT
IAA− chidren
at high genetic
risk for T1D
Planned [123]
Protein GAD Recombinant GAD
in alum (Diamyd) Subcutaneous Swedish Diamyd
(Phase II)
Recent-onset
T1D
Slower decline in
fasting and stimulated
C-peptide secretion;
increase in anti-GAD
aAbs and in FowP3 and
TGF-β mRNA
[32]6 Clinical and Developmental Immunology
Table 1: Continued.
Antigen
type Antigen Formulation Route Trial (Phase) Subjects Outcome and/or
immune biomarkers Reference
Protein GAD Recombinant GAD
in alum (Diamyd) Subcutaneous EU Diamyd
(Phase III)
Recent-onset
T1D Ongoing NCT
00723411
Protein GAD Recombinant GAD
in alum (Diamyd) Subcutaneous
US Diamyd
(DIAPREVENT)
(Phase III)
Recent-onset
T1D Ongoing NCT
00751842
Protein GAD Recombinant GAD
in alum Subcutaneous
NIDDK/ADA/JDRF
GAD-alum
(Phase II)
Recent-onset
T1D Ongoing NCT
00529399
Protein GAD Recombinant GAD
in alum (Diamyd) Subcutaneous DIAPREV-IT
(Phase II)
At risk, GAD
aAb++ ≥1
other aAb
Ongoing NCT
01122446
Peptide Insulin
Insulin B chain in
incomplete Freund’s
adjuvant
Intramuscular IBC-VS01
(PhaseI)
Recent-onset
IAA+ T1D
Increased TGF-β
production [66]
Peptide Proinsulin PIC19−A3 Intradermal
PI peptide
immunotherapy
(PhaseI)
Long-standing
T1D
Transient PI-speciﬁc
IL-10 secretion in 3/18
patients at 30μg
[67]
Modiﬁed
peptide Insulin NBI-6024
(B9–23 APL) Subcutaneous NBI-6024-0003
(PhaseI)
Recent-onset
T1D
Shift from Th1 to Th2
responses [76]
Modiﬁed
peptide Insulin NBI-6024
(B9–23 APL) Subcutaneous
Neurocrine
NBI-6024
(Phase II)
Recent-onset
T1D No eﬀect [77]
Modiﬁed
protein Insulin
Insulin-coupled
ECDI-ﬁxed
autologous
leukocytes
? ITN insulin-coupled
leukocytes At risk Planned [86]
DNA
plasmid Proinsulin BHT-3021
(PI plasmid) Intramuscular Bayhill BHT-3021
(PhaseI)
Recent-onset
T1D Ongoing NCT
00453375
Ag-
speciﬁc
cell
therapy
None
Autologous
monocyte-derived
DCs treated with
CD40/CD80/CD86
antisense
oligonucleotides
Intradermal Pittsburgh DC
vaccine (Phase I)
Long-standing
T1D Ongoing NCT
00445913
median of 4.3 years. Also, in this case, no signiﬁcant protec-
tion was induced, in line with the negative results of smaller
trials [46–48]. However, analysis of a subgroup positive for
IAAsuggested a potential beneﬁt, as the annualized T1D rate
was 6.2% with oral insulin and 10.4% with placebo [49].
It is possible that the intervention may be more eﬀective in
these individuals due to a more active autoimmunity against
insulin. This observation has prompted a new oral insulin
trial focused on IAA+ at-risk subjects (ClinicalTrials.gov
NCT00419562). It also underlines the importance of a
through autoimmunity proﬁling tooptimize enrollment (see
below).
Similar prevention and intervention trials using intran-
asal insulin administration proved safe but did not yield
significant T1D protection [50–52]. One further prevention
trial is ongoing (ClinicalTrial.gov NCT00336674). Interest-
ingly, no study has so far tried to administer PI rather
than insulin. This could be attractive for a number of
reasons. First, PI has a much lower aﬃnity for the insulin
receptor. Although it could be degraded into insulin once
administered, the window of safe doses not engendering
hypoglycemia could be wider. Second, a number of critical
epitopes have been described which are speciﬁc of PI, as they
reside either in the C peptide or at its junction with the B
chain [19, 53]. Important epitopes have also been described
which are speciﬁc of PPI, as they lie in the leader sequence
[19, 34, 54]. Although PPI is more diﬃcult to produce due
to its lower solubility in water, this characteristic could be
even advantageous to obtain a depot eﬀect once injected
subcutaneously.
6.2. GAD. In a recent intervention trial, Ludvigsson et al.
treated new-onset (<18mo) T1D children positive for anti-
GAD aAbs with two subcutaneousinjections of GAD (20μg)
or placebo in alum adjuvant and followed this children
for 30 months. Although there was no change in insulinClinical and Developmental Immunology 7
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Figure 2: Ag-speciﬁc immune therapies. Diﬀerent Ag formulations can be administered via diﬀerent routes, triggering various tolerance
mechanisms. APC: Ag-presenting cell; DC: dendritic cell; i.d.: intraderma l ;i . m . ,i n t r a m u s c u l a r ;i . v . :i n t r a v e n o u s ;M D S C s :m y e l o i d - d e r i v e d
suppressor cells; PBMC: peripheral blood mononuclear cell; s.c.: subcutaneous; Tregs: regulatory T cells.
requirements, there was a slower decline in the fasting
and stimulated C-peptide secretion (a common measure
of residual β-cell function). Importantly, this eﬀect was
observed only in those patients treated within 6 months
of diagnosis. Similar observations have been made in other
clinical trials, such as the European anti-CD3 trial, where
lower insulin requirements were observed only in those
patients who had higher residual β-cell function at the time
of enrollment [55]. Taken together, they suggest that “the
earlier thebetter,”and thatinterventionsata preclinicalstage
would be much more beneﬁcial.
In the GAD trial, the eﬀect on C-peptide secretion was
accompanied by an increase in anti-GAD aAb titers and
in mRNA expression of FoxP3 and transforming growth
factor(TGF)-βinperipheralbloodmononuclearcells,which
could suggest a regulatory switch. It may be counter-intu-
itive that the GAD vaccine is administered along with an
alum adjuvant, which is known to favor immunogenic
ratherthantolerogenicresponses,especiallywiththe“prime-
boost” strategy used in this trial. This peculiarity may raise
the possibility that the therapeutic eﬀect may be due, at
least in part, to the high titers of anti-GAD Abs induced
after vaccination [56]. Indeed, a protective eﬀect of anti-
islet aAbs has been evoked to explain the lower T1D risk
observed in the oﬀspring of aAb+ T1D mothers compared
to aAb-negative ones [57]. Alternative strategies using GAD
vaccination in the absence of adjuvant would be equally
worth testing. Larger intervention trials using the GAD
alum preparation are in progress in Europe and US and
will allow to validate the eﬀect on C-peptide secretion and
to further explore its immune correlates (ClinicalTrials.gov
NCT00723411, NCT00751842, and NCT00529399). A pre-
vention trial is also in progress in Sweden (NCT01122446).
7.Peptides
Peptides have the signiﬁcant edge of being easier to synthe-
size at high purity than recombinant proteins. Long peptides
may have the advantage of covering multiple epitopes, thus
targeting diﬀerent T-cell speciﬁcity. Moreover, the use of
long peptides requires processing before loading on HLA
molecules. This requirement may allow some selectivity
in the Ag-presenting cells targeted, as only professional
Ag-presenting cells—most notably immature, tolerogenic
dendritic cells—can eﬃciently process and present exoge-
nous peptides. However, there are also multiple drawbacks
comparedtoproteinAgs.First, althoughpeptidesaresmaller
molecules and thus deliver up to 50 times more agent on a
weight-for-weight basis when compared with protein Ags,
the life span of peptides in blood—and likely in other
tissues—is very short, in the order of minutes [58]. Second,
peptides (but also epitopes processed from protein Ags) may
be presented in alternative ways, thus triggering unwanted
T-cell activation [59, 60]. Third, the same peptide dose can
trigger diverse eﬀects on diﬀerent T cells, depending on their
relative Ag avidity (e.g., simple activation versus activation-
induced apoptosis) [61, 62]. Fourth, activation-induced8 Clinical and Developmental Immunology
apoptosis, which is one of the mechanisms through which
peptides may work, develops through a phase of deleterious
activation before driving T cells to death. The drawbacks of
this type of peptide-based approaches are exempliﬁed by the
disappointing results obtained on multiple sclerosis patients.
T w oc l i n i c a lt r i a l sw e r ep r e m a t u r e l yt e r m i n a t e db e c a u s eo f
disease ﬂare-ups rather than remissions [63–65]. Although
these trials employed altered peptide ligands (see below), the
same caveats may apply to native peptides.
There is no suﬃcient hindsight from T1D clinical trials
to judge whether these theoretical hurdles are encountered.
In a Phase I study on 12 new-onset T1D patients, a sin-
gle intramuscular administration of insulin B chain (i.e.,
a 30-amino-acid polypeptide) or placebo in incomplete
Freund’s adjuvant was safe and induced robust insulin-
speciﬁc humoral and T-cell responses but no diﬀerence in
stimulated C-peptide responses. Given the small sample size
and patients’ recruitment irrespective of residual C-peptide
secretion, it is not possible to draw conclusions concern-
ing clinical eﬃcacy. However, B-chain-stimulated CD4+ T
cells from B-chain-treated patients exhibited higher TGF-
β secretion in the ﬁrst 3 months after treatment as com-
pared to T cells from placebo-treated patients, yielding
clones with proﬁles suggestive of a regulatory phenotype
[66].
AP h a s eIc l i n i c a lt r i a lw i t haD R ∗04:01-restricted PI
peptide C19-A3 in long-standing (>5 years) T1D patients
has also been reported [67]. This trial employed intradermal
administration at a dose of 30 or 300μg repeated 3 times
within 2 months, enrolling 18 patients in each arm (peptide
versus no treatment). The therapy was well tolerated and
did not induce proinﬂammatory reactivation of PI-speciﬁc
T cells, but rather transient PI-speciﬁc IL-10 secretion in 3
of the 18 patients treated at the lower dose. As is the case for
PhaseItrials,theaimofthisstudywastoassesssafetyandnot
clinical eﬃcacy, and the inclusion criteria reﬂect this ratio-
nale (long-standing T1D patients with glucagon-stimulated
Cp e p t i d e≤0.2nmol/L; control group left untreated, i.e., no
placebo). Although the observed safety proﬁle is reassuring,
it should be noted that PI-speciﬁc T-cell responses were
not detectable at baseline in these long-standing patients,
contrarytowhatpreviouslyobservedinnew-onsetones[68].
Thus, theeﬀectofpeptideadministration may bediﬀerentin
t h ep r e s e n c eo fr e c e n t l yin vivo primed PI-speciﬁc T cells and
of a higher residual β-cell mass.
Clinical trials with a peptide derived from the heat-shock
protein (hsp60) immunodominant epitope 437–460 (Dia-
Pep277) showed marginally preserved endogenous insulin
production in some newly diagnosed T1D patients [69, 70].
The mechanism by which the DiaPep277may function is not
completely understood. Qualifying hsp60 as a target Ag in
T1D autoimmunity is debatable, and alternative, non-Ag-
speciﬁc mechanisms are possible. Indeed, hsp60 has been
shown to activate T cells via the Toll-like receptor 2 and
to inhibit T-cell chemotaxis [71]. This pathway could also
induce the shift from T helper (Th)1 to Th2 cytokines
observed in humans. Thus, this mode of action would
categorizeDiaPep277asasystemicratherthananAg-speciﬁc
immune modulator.
8.Modiﬁed Proteinand PeptideAgs
Disarming pathogenic T cells by modifying the epitopes
they recognize at key amino acid positions is an option
that has been sought in several autoimmune diseases. TCR
interaction with these modiﬁed epitopes, called altered
peptide ligands (APLs), can result in only partial activation
and dramatically diﬀerent T-cell phenotypes, ranging from
inducing selective stimulatory functions to completely turn-
ing oﬀ their functional capacity [72]. The central role of
the insulin B9–23 epitope in the NOD mouse [23, 73]a n d
its immunodominance in T1D patients [74] led to develop
an APL version called NBI-6024. This B9–23 APL showed
promising results in NOD mice [75]. Results of a Phase I
clinical study on recent-onset T1D patients suggested that
NBI-6024 treatment shifted Th1 responses to a Th2 pheno-
type[76].However, asubsequent Phase II,dose-ranging trial
testing repeated NBI-6024 subcutaneous treatment at 0.1,
0.5, or 1mg did not preserve β-cell function [77]. Clinical
trials with APLs in multiple sclerosis further chilled down
enthusiasm for this approach. Two Phase II trials with a
myelin basic protein APL were prematurely terminated, as
treatment led to disease exacerbations and hypersensitivity
reactions [63, 64]. This dramatic experience underlines the
difﬁculty of developing one single APL which would induce
t h es a m ee ﬀect on all cognate T cells. It is possible that the
APLeﬀectmaybedependentonparameterssuchaseffect-ive
dose delivered and T-cell avidity, activation status and phe-
notype, and thus trigger diﬀerent polarizing signals [65].
As DCs present Ags in a tolerogenic manner in the steady
state, for example, in the absence of infection or inﬂamma-
tion, selective Ag delivery to DCs promotes tolerance in the
absenceofmaturationstimuli[78–80].Tothisend,anumber
of mAbs against endocytic receptors expressed by DCs have
been developed, with the aim of using them to target Ag
delivery. DEC-205 (CD205) is one of such receptors, which
is expressed on the CD8+ DC subset capable to eﬃciently
cross-present [81]. Besides selective targeting, this in vivo Ag
delivery approach would obviate the need for leukapheresis
and ex vivo DC manipulation. On these grounds, the group
of T. DiLorenzo delivered the IGRP mimotope NRP-V7 in
vivo to murine DCs by fusing it with an anti-DEC-205
mAb. Proliferation of transferred NRP-V7-speciﬁc T cells
was initially observed, but this was followed by deletion.
T o l e r a n c ew a sa c h i e v e db e c a u s er e c h a l l e n g eo fm i c ew i t h
NRP-V7 in adjuvant did not induce an immune response.
NRP-V7 delivery through DEC-205 was tolerogenic only
when performed in the steady state. As expected, co-
administration of anti-CD40 mAb and polyI:C to mature
DCs led instead to enhanced expansion of transferred T cells
[82]. Although evidence of T1D protection is still missing,
this approach may prove of great interest when combined
with suitable epitopes. Moving towards this direction, the
feasibility of DEC-205 delivery of the entire PPI molecule isClinical and Developmental Immunology 9
under investigation [83]. This would facilitate translation to
patients expressing diverse MHC molecules.
Another original system of tolerogenic Ag delivery
has been developed by Miller and coworkers [84–86].
This consists in administration of self peptides covalently
cross-linked to cells via ethylene carbodiimide (ECDI). In
preclinical models of various autoimmune diseases, this
approach involvesECDIcross-linking ofselfproteinsorpep-
tides to syngeneic splenocytes. Intravenous injection of these
A g - c o u p l e ds p l e n o c y t e si sh i g h l ye ﬀective at inducing toler-
ance for both prevention and treatment of various autoim-
mune diseases in mouse models, including experimental
autoimmune encephalomyelitis (a mouse model of multiple
sclerosis) [87]a n dT 1 Di nt h eN O Dm o u s e[ 88]. Ag-coupled
splenocytes behave like apoptotic bodies and are rapidly
uptaken by Ag-presenting cells, much more eﬃciently than
soluble protein or peptide Ags [89]. Ag presentation leads
to tolerance induction by inducing Ag-speciﬁc T-cell unre-
sponsiveness via two synergistic mechanisms: programmed
death(PD)-1/PDligand 1-mediated anergy and T regulatory
cell (Treg) activation [88]. Processing and presentation of
Ags coupled to apoptotic bodies gives the advantage of
inducing tolerance by cellular carriers ﬁxed with peptides,
intact proteins, or even crude homogenates of the target
organ [87]. This tolerogenic system is currently being tested
inmultiplesclerosis,usingECDI-ﬁxedautologousperipheral
blood leukocytes coupled with a cocktail of seven myelin
peptides. A similar trial using insulin-coupled autologous
leukocytes for prevention of T1D is under development by
the Immune Tolerance Network.
9.DNA Plasmids
DNA vaccines are the simplest embodiment of vaccines that,
rather than consisting of the Ag itself, provide genes for
endogenous synthesis of the protein Ag. The idea stemmed
from the need to eﬃciently deliver protein and polypep-
tide Ags to the MHC Class I pathway for presentation to
and stimulation of CD8+ T-cell responses. Inducing such
responses with exogenous protein Ags is not eﬃcient, as
it requires cross-presentation, a requirement which can
be fulﬁlled mostly if not exclusively by specialized DC
subsets. As DNA-encoded Ags are endogenously translated
by transfected cells, DNA immunization has the potential to
result in conventional priming as well as cross-priming.
There are many ways to eﬃciently deliver DNA vaccines
[90], and this strategy has been exploited for many research
applications such as T-cell epitope identiﬁcation [91, 92].
One strategy consistsofbombarding theepidermiswith gold
microbeadscoatedwith plasmid,which candirectlytransfect
Langerhans cells causing their rapid migration to draining
lymph nodes. Alternatively, plasmids can be intramuscularly
injected, leading to predominant transfection of myocytes
and less eﬃcient Ag presentation. This latter approach
is currently been explored for tolerance induction, using
a plasmid encoding for proinsulin (BHT-3021) in T1D
patients with less than 5 years of disease (ClinicalTrials.gov
NCT00453375).The relatively long disease durationused for
patient recruitment and the low potency of DNA vaccines
documented in other clinical trials may be important factors
in the ﬁnal outcome.
10.Ag-SpeciﬁcCellTherapies
Ag-speciﬁc tolerance restoration could be induced not only
by using suitable Ag proteins or peptides, but also by adopt-
ively transferring cells armed to be selective for the targets
of choice. These approaches are being explored for Tregs and
DCs [93].
Expansion protocols to obtain high numbers of CD4+
Tregs suitable for in vivo cell therapies have been developed
for both mouse and human [94–97]. However, these cells
remain polyclonal in nature although a shortcut has been
obtained in murine models by expanding T cells from mice
transgenic for a T-cell receptor which recognizes a speciﬁc
β-cell epitope such as BDC2.5. Although some pioneering
reports of expanded human β-cell Ag-speciﬁc Tregs have
been published [98, 99], it is not clear whether these
cells would have suitable characteristics to exert therapeutic
eﬀects once transferred in vivo. Further incertitude is added
by a recent paper describing that polyclonal murine CD4+
Tregs can revert their phenotype after in vivo transfer,
losing FoxP3 expression and acquiring pathogenic potential.
Indeed, these “ex-Tregs” were found to accumulate sponta-
neously in the insulitis of NOD mice, suggesting that this
phenomenon may not be peculiar of transfer settings. Even
more worryingly, these ex-Tregs were capable of eﬃciently
transferring disease, similar tostandard Teﬀectorcells[100].
Another cell-based approach consists of loading imma-
ture DCs with the Ag of interest. This type of approach
has previously been shown to be eﬃc i e n ta tp r o m o t i n gA g -
speciﬁc immune tolerance [101, 102]. This strategy is now
being tested for T1D intervention in a Phase I safety study
led by M. Trucco. Tolerogenic autologous monocyte-derived
DCs are being generated by treating them ex vivo with anti-
sense oligonucleotidestargeting the CD40, CD80, and CD86
costimulatory molecules [103]. These modiﬁed DCs are
being compared with control autologous monocyte-derived
DCs left untreated. The fact that intravenously administered
bone-marrow-derived DCs accumulate predominantly in
the spleen and the pancreatic and tracheal lymph nodes
[104] justiﬁes the choice of not loading these DCs with
exogenous Ag. These DCs may acquire islet Ags in vivo in
pancreatic lymph nodes and could thus modulate eﬀector
and regulatory T-cell responses to T1D-relevant Ags even
without deliberate prior Ag loading. The other peculiarity
of this trial is that DCs (which are not used fresh but
cryopreserved) will be administered intradermally closest to
the physical location of the pancreas, as both sites may drain
to the same lymph nodes (ClinicalTrials.gov NCT00445913).
Importantly, preclinical studies suggest that the therapeutic
eﬀectoftheseunloadedtolerogenicDCsremainsAg-speciﬁc,
assplenicTcellsfromtreated miceproliferatedtoallo-Agsex
vivo[103].
Another cell population which may soon be tested for
cell-based immunotherapy is myeloid-derived suppressor10 Clinical and Developmental Immunology
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Figure 3:“Immunestaging”ofT1D. Biomarkersofβ-cell autoimmunitysuchas aAbs andT cells could help to identify at-risk subjects atan
early stage (preclinical diagnosis)and to follow them up over time to decide the need for immune therapy and the best timing for treatment
(prognosticstratiﬁcation).Ag-speciﬁc immunetherapy could be personalized for each subject by administeringtherapeutic formulationsof
thoseAgs targeted by aAband/orT-cell responses.Modiﬁcationsinduced on such responsescouldbe followedin real time during treatment,
thus allowing to assess immune eﬃcacy prior to and independent of clinical outcome.
cells (MDSCs). These are cells of myeloid origin with
immunoregulatory activity that cansuppressAg-speciﬁc and
nonspeciﬁc T-cell responses via diﬀerent mechanisms in
cancer [105–107], transplantation [108], and T1D [109].
Pre-clinical study testing the protective role of these cells in
T1D were performed in RIP-HA mice transferred with HA-
speciﬁc CD4+ T cells, where it was shown that HA-loaded
MDSCscouldactasAPCsin anAg-speciﬁcfashion toinduce
anergy of eﬀector T cells, development of Tregs, and T1D
prevention [109].
11.The ImportanceofImmune
SurrogateMarkers
In light of the formidable challenge of rescuing a signiﬁcant
β-cell mass in already diabetic patients, it is important to
evaluate not only clinical (lower HbA1c values and reduced
insulin requirements) and metabolic (C-peptide secretion)
endpoints, but also immune surrogate endpoints. This is
even more important in trials not showing clinical beneﬁt,
ornotpoised to detectsuch beneﬁts, asiscommonly thecase
forphase Istudies. Indeed,thelackofclinicaleﬀectscouldbe
open to disparate interpretation, including late treatment in
front of full-blown disease, the need to target multiple Ags
in advanced T1D once epitope spreading has occurred, or
failure to restore immune tolerance. These possibilities can
be sorted out by immune monitoring analyses performed
before, during, and after treatment, particularly by scruti-
nizing changes induced in T-cell responses speciﬁc to the
administered Ag (Figure 3). Validation and standardization
of blood sample processing and T-cell assay procedures is an
i m p o r t a n tg o a lt ot h i se n d[ 110–112].
We recently reported a proof-of-concept study on aAb+
diabetic patients not requiring insulin at the time of
diagnosis. These patients were treated with intranasal insulin
in an attempt to save residual β cells. Although nasal
insulintreatedpatientseventuallyprogressedtowardsinsulin
dependency at a rate similar to placebo-treated ones, we
could document successful induction of insulin-speciﬁc
immune tolerance both at the T-cell and antibody level [52].
Contrary to what observed in the placebo arm, patients
treated with intranasal insulin displayed signiﬁcant reduc-
tions in frequencies of interferon-γ-secreting PI-speciﬁc T-
cellresponses, usinghighsensitivityT-cellassaysthatamplify
responses by means of an accelerated cocultured DC (acDC)
stimulation (Martinuzzi et al., under revision). This eﬀect
was Ag-speciﬁc, as it was not observed for responses towards
the tetanus toxoid recall Ag. The initiation of insulin therapy
further documented that this PI-speciﬁc tolerance was oper-
ational in vivo, as intranasal insulin treated subjects failed to
develop anti-insulin antibodies [52]. These results suggest
that this intervention is immunological eﬀective, but not
suﬃcient to rescue β cells, probably because administered
too late, at an advanced stage where most islets have already
disappeared and β-cell autoimmunity has already spread
too far on additional Ag speciﬁcities. Knowing whether
Ag-speciﬁc T-cell responses are modiﬁed and in which
individuals provides key mechanistic information to plan
further trials and modify therapeutic strategies accordingly.
This information may also be critical to optimize enrollment
strategies. Indeed, pretreatment testing for T-cell reactivitiesClinical and Developmental Immunology 11
could allow to focus enrollment on those patients displaying
active insulin-speciﬁc autoimmune responses, as there might
be little beneﬁt in treating those who do not harbor
such responses (Figure 3). Imaging techniques allowing to
visualize β-cell mass and inﬁltration will provide additional
tools for immune-based pretreatment staging and post-
treatment monitoring [113].
12.CombinationTherapies
Despite the mentioned evidence in the NOD mouse for an
initiating role of insulin as the primary β-cell Ag target, the
same principle may not apply to outbred humans, due to the
variablegenetic and environmental backgroundand thelater
timing of intervention and even prevention trials, at a stage
whereepitopespreading islikelytohaveoccurred.Therefore,
strategies where multiple β-cell Ags (e.g., PI and GAD) are
combined may yield synergistic eﬀects and more substantial
clinical beneﬁt. This possibility will certainly be explored in
upcomingclinicaltrials.Anotheroptionunderconsideration
consists of combining Ags with immune modulatory mAbs
such as anti-CD3 and anti-CD20, which have already been
trialed alone, sometimes with encouraging results [114].
Besides the potential for synergy, this approach may allow
to reduce mAb dosing, thus limiting unwanted side eﬀects
and facilitating repeated treatment [115–117]. Combination
of tolerogenic strategies with approaches aimed at replacing
[118, 119] or regenerating [120] β cells are also attractive,
as they may allow to intervene at later stages. Although a
ﬁrst clinical trial testing exenatide alone or in combination
with daclizumab did not show any eﬀect [121], other agents
and combinations thereof need to be tested before drawing
deﬁnite conclusions.
13.Conclusions
We are moving towards a new era of clinical trials in T1D,
where the long-sought goal of Ag-speciﬁc immune tolerance
is becoming at reach. To turn these promises into reality, it
will be important to comparatively evaluate several aspects
thatremain poorly deﬁned. (1)Administration routes:intra-
venous, subcutaneous, intradermal, and mucosal. Regarding
the latter, it is surprising that only oral and intranasal
routes have been investigated for T1D, leaving out the
sublingual approach despite its successful track record for
allergydesensitization[122].(2)Agdose,identifyingsuitable
therapeutic ranges, which will critically depend on the
nature of the Ag and the route of administration. We have
discussed the hurdles of translating the insulin doses used
in NOD mouse studies into clinical trials. Importantly,
diﬀerence insulin formulations may widen the therapeutic
window. Another key diﬀerence between preclinical and
human studies is the timing of intervention. A proposed
primary prevention trial (Pre-POINT) [123] aims to address
this issue of disease stage by intervening with oral or nasal
insulin in children genetically predisposed to T1D, before
the appearance of the ﬁrst signs of β-cell autoimmunity
(i.e., in children who have not yet developed IAA). (3)
Frequency and interval of administration, keeping in mind
that approaches promoting longer persistence of low Ag
loads may be beneﬁcial over high-load spikes [43]. Ancillary
mechanistic studies should accompany these trials to clarify
modes of action and help optimizing the risk-to-beneﬁt
ratio.AutoimmuneT-cellproﬁlingmaybeparticularlyuseful
for tailoring and monitoring treatment in each individual
patient.
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